Biocon secures EMA approval for Semglee production line
after close1 source ↓written by the desknot a recommendation
- with shares rising
- 0.6% to ₹437.2
- saw Mylan sell
- ₹3,680 cr block deal
Biocon received EMA approval for its Semglee insulin production line at the Malaysian facility, facilitating shipments expected in FY27. This development has positively impacted investor sentiment, with shares rising 0.6% to ₹437.2. A recent ₹3,680 cr block deal saw Mylan sell shares, attracting interest from Indian mutual funds.
Not investment advice. For informational purposes only.